4D Molecular Therapeutics, Inc. Proceeds from Common Stock Issued
4D Molecular Therapeutics, Inc. (FDMT) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-03-15
- 4D Molecular Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- 4D Molecular Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2021 was $114.30M, a 44.42% decline from fiscal 2020.
- 4D Molecular Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $205.66M.
| Period end | Proceeds from Issuance of Common Stock 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2021-12-31 | $114.30M 10-K · filed 2023-03-15 |
| 2020-12-31 | $205.66M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |